Urapidil enhances subcutaneous tissue oxygen tension during convective rewarming of mildly hypothermic rats
✍ Scribed by K.P. Ittner; M. Pawlik; M. Zimmermann; K. Taeger; L. Faerber
- Book ID
- 104034951
- Publisher
- Elsevier Science
- Year
- 2006
- Tongue
- English
- Weight
- 245 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0306-4565
No coin nor oath required. For personal study only.
✦ Synopsis
To investigate whether urapidil (a 1 -adrenergic antagonist/5-HT 1A agonist) enhances subcutaneous tissue oxygen tension (P sq O 2 ) during convective rewarming, we performed a prospective, randomized, placebo-controlled animal study. Mild hypothermia was achieved by surface cooling. Protocol A: before rewarming : i.v. bolus of 1.0 ml NaCl 0.9%/kg body weight; Protocol B: before rewarming: i.v. bolus of 5 mg urapidil/kg body weight.
Urapidil significantly reduced the rewarming time (placebo: 30.272.9 min, urapidil: 24.272.3 min, P ¼ 0:012) and the P sq O 2 during rewarming was significantly enhanced (P ¼ 0:023, AUC PsqO 2 -placebo versus AUC PsqO 2 -urapidil ).
The a 1 -adrenergic antagonist/5-HT 1A agonist urapidil accelerates convective rewarming and enhances P sq O 2 during rewarming in mildly hypothermic rats. Obviously, urapidil therapy increased the shift of heat from the periphery to the core. It is known that 5-HT 1A receptor agonists reduce thermoregulatory thresholds to cold. Therefore, a reduction in oxygen consumption with an increased oxygen delivery to subcutaneous tissues by urapidil is a further possible mechanism.